A Phase 4 interventional study of Tacrolimus and Sirolimus in Graft Rejection, Kidney Transplant and Renal Allograft Recipients, sponsored by Pfizer. Completed at 44 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-18.
Sponsored by Pfizer · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will look at the effect on long-term kidney function using tacrolimus right after a transplant and then switching to sirolimus at 3 to 5 months after the transplant.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At Screening:
At Randomization:
Exclusion Criteria:
At Screening:
At Randomization:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tacrolimus · Drug: Sirolimus
Drug: Tacrolimus
During the screening phase, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is from transplantation until randomization (from 90 to 150 days).
Also known as: Prograf, Adagraf
Following randomization, sirolimus is provided by the Sponsor in 1 and 2 mg oral tablets. Sirolimus is dosed once daily to achieve a target trough level of 7 to 15 ng/mL in the 1st year post-transplant and 5 - 15 ng/mL in the 2nd year post-transplant. Duration of treatment is from randomization through 2 years post-transplant (19 to 21 months).
Also known as: Rapamune
During the study, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is 2 years post-transplant.
Also known as: Prograf, adagraf
Percentage of Participants With Improvement of Greater Than or Equal to [≥]5 Milliliters Per Minute Per 1.73 Square Meters (mL/Min/m^2) in Calculated Glomerular Filtration Rate (GFR) at 24 Months Post-Transplantation (On-Therapy Analysis)
GFR was calculated using the Modified Diet in Renal Disease (MDRD) equation using either serum creatinine traceable to isotope dilution mass spectrometry (IDMS) or serum creatinine not traceable to IDMS.
Time frame: Baseline, Month 24
Percentage of Participants With Improvement of ≥5 mL/Min/m^2 in Calculated GFR at 12 Months Post-Transplantation (On-Therapy Analysis)
GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS.
Time frame: Baseline, Month 12
Percentage of Participants With Improvement of ≥5 mL/Min/m^2 in Calculated GFR at 12 and 24 Months Post-Transplantation (Intent-to-Treat [ITT] Analysis)
GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS.
Time frame: Baseline, Months 12 and 24
Percentage of Participants With Improvement of ≥7.5 mL/Min/m^2 in Calculated GFR at 12 and 24 Months Post-Transplantation
GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS.
Time frame: Baseline, Months 12 and 24
Percentage of Participants With Improvement of ≥10 mL/Min/m^2 in Calculated GFR at 12 and 24 Months Post-Transplantation
GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS.
Time frame: Baseline, Months 12 and 24
Calculated GFR Using MDRD (On-Therapy Analysis)
GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS. Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article.
Time frame: Baseline, Months 6, 12, 18, and 24
Change From Randomization in Calculated GFR Using MDRD (On-Therapy Analysis)
GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS. Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article.
Time frame: Baseline, Months 6, 12, 18, and 24
Slope of Calculated GFR (MDRD) From Randomization to 24 Months Post-Transplantation (On-Therapy Analysis)
GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS. Timepoints were calculated as study days, relative to the time of randomization of study medication. All available on-therapy values were included. Observed data were multiplied by a scale factor of 365, expressing the slope as an annual change.
Time frame: Baseline, Month 24
Serum Creatinine (On-Therapy Analysis)
Serum creatinine was measured in micromillimoles per liter (mcmol/L). Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article.
Time frame: Baseline, Months 6, 12, 18, and 24
Change From Randomization in Serum Creatinine (On-Therapy Analysis)
Serum creatinine was measured in mcmol/L. Baseline was defined as the last assessment prior to first administration of study drug.
Time frame: Baseline, Months 6, 12, 18, and 24
Percentage of Participants With Biopsy-Confirmed Acute Rejection (BCAR), Graft Loss, or Death From Randomization to 24 Months Post-Transplantation
Biopsy-confirmed acute rejection was defined according to updated Banff criteria (2007) for renal allograft rejection. Graft loss was defined as physical loss (nephrectomy or retransplantation), functional loss (requiring dialysis for greater than or equal to \[≥\]56 days with no return of graft function), or death.
Time frame: Post-randomization to Month 24 post-transplantation
Percentage of Participants With Graft Loss (Including Death) at 12 and 24 Months Post-Randomization
Graft loss was defined as physical loss (nephrectomy or retransplantation), functional loss (requiring dialysis for ≥56 days with no return of graft function), or death.
Time frame: Post-randomization to Months 12 and 24 Post-Transplantation
Percentage of Participants With BCAR Post-Randomization to 6, 12, 18, and 24 Months Post-Transplantation
BCAR was defined according to updated Banff criteria (2007) for renal allograft rejection.
Time frame: Post-Randomization to 6, 12, 18, and 24 months Post-Transplantation
Percentage of Participants With First On-Therapy BCAR From Transplantation Occurring at 12 and 24 Months
Defined as the first BCAR occurring during the On-Therapy period based on the ITT population. Time to first BCAR was the days from transplantation to the date of BCAR.
Time frame: Months 12 and 24
Number of Participants With BCAR by Severity of First BCAR and Time of Onset From Post-Randomization to 6, 12, 18, and 24 Months Post-Transplant
BCAR was categorized as antibody-mediated (AM) or T-cell. AM BCAR severity was graded as Grade I (mild), Grade II (moderate), and Grade III (severe). T-cell BCAR severity was graded as 'Grade Ia, Ib (mild), Grade IIa, IIb (moderate), and Grade III (severe). If a participant had both T-cell BCAR and antibody-mediated BCAR on the first rejection, the participant was counted in each category.
Time frame: Months 6, 12, 18, and 24
Percentage of Participants With Antibody Use in Treatment of Acute Rejection
Number of participants who experienced an adverse event (AE) of rejection was used as the denominator in the determination of percentage of participants with antibody use in treatment of acute rejection.
Time frame: On Therapy Period (up to 21 months post-randomization) and Off-Therapy Period (up to 24 months post-transplantation)
Percentage of Participants With Anemia, Thrombocytopenia, or Leukopenia
Anemia was defined as hemoglobin less than or equal to (≤)10 grams per deciliter (g/dL); leukopenia was defined as white blood cell (WBC) count ≤2000 per cubic millimeters (/mm\^3); and thrombocytopenia was defined as platelets ≤100,000/mm\^3. Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article.
Time frame: Baseline, Months 12 and 24
Change From Baseline (Pre-Randomization) to 12 and 24 Months Post-Transplantation in Fasting Lipid Parameters (Millimoles Per Liter [mmol/L])
Parameters assessed included total cholesterol (TC), triglycerides, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C); collected when participant was in a fasting state.
Time frame: Baseline, Months 12 and 24
Percentage of Participants Requiring Anti-Hypertensive Medication, Diabetes Agents, Lipid-Lowering Agents, or Erythropoiesis Stimuating Agents (ESAs)
Time frame: Baseline, Months 12 and 24
Spot and 24 Hour Urine Protein to Creatinine Ratio (UPr/Cr)
Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article.
Time frame: Baseline and Months 12 and 24
Percentage of Participants With Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor Block (ARB) Use
Included ACEI or ARB use prior to randomization, during the on-therapy period (up to 19 to 21 months post randomization) and the off-therapy period (up to 24 months post-transplantation).
Time frame: Pre-randomization, On-Therapy Period (up to 21 months post-randomization), and Off-Therapy Period (up to 24 months post-transplantation)
Percentage of Participants With Stomatitis
Includes adverse events based on categorization by the investigator as stomatitis, regardless of the event preferred term in Medical Dictionary for Regulatory Activities (MedDRA)
Time frame: From randomization up to 24 months after transplantation (On-Therapy)
Percentage of Participants Requiring Treatment for Stomatitis by Treatment Type
Included treatments (analgesics, dental paste, topical antifungal, topical steroids, or other) prior to randomization, during the on-therapy period (up to 19 to 21 months post-randomization) and the off-therapy period (up to 24 months post-transplantation).
Time frame: On-Therapy Period (up to 21 months post-randomization) and Off-Therapy Period (up to 24 months post-transplantation)
Change From Pre-Randomization to 12 Months Post-Transplantation in Hemoglobin A1C (Liter Per Liter [L/L])
Ratio of hemoglobin A1c to normal hemoglobin.
Time frame: Baseline, Month 12
Change From Pre-Randomization to 12 Months Post-Transplantation in Fasting Glucose (mmol/L)
Time frame: Baseline, Month 12
Change From Pre-Randomization to 12 Months Post-Transplantation in Fasting Insulin (Picomoles Per Liter [Pmol/L])
Time frame: Baseline, Month 12
Change From Pre-Randomization to 12 Months Post-Transplantation in Weight (Kilograms [kg])
Time frame: Baseline, Month 12
Change From Pre-Randomization to 12 Months Post-Transplantation in Waist Circumference(Centimeters [cm])
Time frame: Baseline, Month 12
Change From Pre-Randomization to 12 Months Post-Transplantation in Homeostasis Model Assessment Insulin Resistance (HOMA-IR; Fasting)
The HOMA-IR measures insulin resistance based on fasting glucose and insulin measurements: HOMA-IR = fasting plasma glucose (mmol/L) multiplied by (\*) fasting plasma insulin in microunits per liter (µU/L) divided by (/) 22.5. Participants taking insulin within 12 hours were excluded from the analysis.
Time frame: Baseline, Month 12
Change From Pre-Randomization to 12 Months Post-Transplantation in HOMA-Beta Cell (HOMA-B; Fasting)
The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) as a percentage of a normal reference population. HOMA-B = 20 \* insulin (µU/L) / fasting plasma glucose (mmol/L) minus (-) 3.5 Participants taking insulin within 12 hours were excluded from the analysis.
Time frame: Baseline, Month 12
Change From Pre-Randomization to 12 Months Post-Transplantation in Body Mass Index (BMI; in Kilograms Per Square Meter [kg/m^2])
BMI = Weight (kg)/(Height\*Height) (square meters \[m\^2\]).
Time frame: Baseline, Month 12
Percentage of Participants With New-Onset Diabetes
Participants were considered as having new onset diabetes during the On-therapy period if any of the below events emerged from baseline to Month 24: 1) at least 30 days continuous, or at least 25 days non-stop (without gap) use of any diabetic treatment after randomization; 2) a fasting glucose greater than or equal to (≥)126 milligrams per deciliter (mg/dL) after randomization; or 3) a non-fasting glucose ≥200 mg/dL after randomization, were included in the new-onset diabetes population. Events at Months 12 or 24 occurred from baseline to On-therapy Month 12 and from On-therapy Months 12 to 24, respectively.
Time frame: From Baseline to On-Therapy Month 12, from Baseline to On-Therapy Month 24, and from On-Therapy Month 12 up to On-Therapy Month 24
Percentage of Participants With New-Onset Diabetes Receiving Treatment for Diabetes (Insulin and Non-Insulin)
Participants were considered as having new onset diabetes during the On-therapy period if any of the below events emerged between baseline and Month 12 or Month 24: 1) at least 30 days continuous, or at least 25 days non-stop (without gap) use of any diabetic treatment after randomization; 2) a fasting glucose ≥126 mg/dL after randomization; or 3) a non-fasting glucose ≥200 mg/dL after randomization.
Time frame: 12 Months and 24 Months
Percentage of Participants With Infection
Includes adverse events based on categorization by the investigator as 'infection', regardless of the event preferred term in MedDRA.
Time frame: From randomization up to 24 months after transplantation (On-Therapy)
Percentage of Participants With Cytomegalovirus (CMV) Infection
Includes adverse event terms reported by the investigator to be attributed to the organism 'cytomegalovirus', regardless of the preferred term in MedDRA.
Time frame: From randomization up to 24 months after transplantation (On-Therapy)
Percentage of Participants With Polyomavirus Infection
Includes adverse event terms reported by the investigator to be attributed to the organism 'polyomavirus', regardless of the preferred term in MedDRA.
Time frame: From randomization up to 24 months after transplantation (On-Therapy)
Percentage of Participants With Malignancy
Includes any adverse events based on categorization by the investigator as 'malignancy', regardless of the event preferred term in MedDRA.
Time frame: From randomization up to 24 months after transplantation (On-Therapy)
| Milestone | Sirolimus | Tacrolimus |
|---|---|---|
| Started | 131 | 123 |
| Completed | 87 | 111 |
| Not completed | 44 | 12 |
| Withdrew: Adverse event | 28 | 4 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Physician decision | 3 | 1 |
| Withdrew: Lost to follow-up | 1 | 3 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Withdrew: Lack of efficacy | 5 | 0 |
| Withdrew: Other | 0 | 1 |
GFR was calculated using the Modified Diet in Renal Disease (MDRD) equation using either serum creatinine traceable to isotope dilution mass spectrometry (IDMS) or serum creatinine not traceable to IDMS.
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| Percentage of Participants With Improvement of Greater Than or Equal to [≥]5 Milliliters Per Minute Per 1.73 Square Meters (mL/Min/m^2) in Calculated Glomerular Filtration Rate (GFR) at 24 Months Post-Transplantation (On-Therapy Analysis) | 33.7 | 42.2 |
GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS.
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| Percentage of Participants With Improvement of ≥5 mL/Min/m^2 in Calculated GFR at 12 Months Post-Transplantation (On-Therapy Analysis) | 39.4 | 44.8 |
GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS.
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| Month 12 | 38.2 | 42.3 |
| Month 24 | 33.6 | 40.7 |
GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS.
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| Month 12 | 24.4 | 35.8 |
| Month 24 | 25.2 | 30.9 |
GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS.
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| Month 12 | 19.8 | 23.6 |
| Month 24 | 22.1 | 22.0 |
GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS. Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article.
| mL/min/1.73 m^2 | Sirolimus | Tacrolimus |
|---|---|---|
| Baseline (n=131,123) | 58.5 ± 14.3 | 57.4 ± 14.1 |
| Month 6 (n=125,120) | 61.6 ± 14.9 | 57.6 ± 14.2 |
| Month 12 (n=109,116) | 59.6 ± 16.4 | 61.3 ± 14.3 |
| Month 18 (n=99,111) | 60.0 ± 15.0 | 59.8 ± 17.1 |
| Month 24 (n=86,109) | 59.4 ± 18.0 | 58.4 ± 14.9 |
GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS. Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article.
| mL/min/1.73 m^2 | Sirolimus | Tacrolimus |
|---|---|---|
| Month 6 (n=125,120) | 2.7 ± 1.1 | 0.0 ± 0.8 |
| Month 12 (n=109,116) | 1.5 ± 1.2 | 3.4 ± 1.1 |
| Month 18 (n=99,111) | 2.2 ± 1.2 | 1.5 ± 1.3 |
| Month 24 (n=86,109) | 1.2 ± 1.6 | 0.6 ± 1.3 |
GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS. Timepoints were calculated as study days, relative to the time of randomization of study medication. All available on-therapy values were included. Observed data were multiplied by a scale factor of 365, expressing the slope as an annual change.
| mL/min/1.73 m^2 per year | Sirolimus | Tacrolimus |
|---|---|---|
| Slope of Calculated GFR (MDRD) From Randomization to 24 Months Post-Transplantation (On-Therapy Analysis) | -0.9 (-2.7 to 0.8) | 0.9 (-0.7 to 2.5) |
Serum creatinine was measured in micromillimoles per liter (mcmol/L). Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article.
| mcmol/L | Sirolimus | Tacrolimus |
|---|---|---|
| Baseline (n=131,123) | 118.3 ± 24.8 | 117.7 ± 27.9 |
| Month 6 (n=125,120) | 113.9 ± 27.6 | 117.0 ± 28.2 |
| Month 12 (n=109,116) | 119.6 ± 37.5 | 109.4 ± 24.6 |
| Month 18 (n=99,111) | 116.9 ± 33.1 | 114.2 ± 30.4 |
| Month 24 (n=86,109) | 122.9 ± 48.8 | 117.5 ± 42.8 |
Serum creatinine was measured in mcmol/L. Baseline was defined as the last assessment prior to first administration of study drug.
| mcmol/L | Sirolimus | Tacrolimus |
|---|---|---|
| Month 6 (n=125,120) | -4.1 ± 2.0 | -0.0 ± 1.4 |
| Month 12 (n=109,116) | -0.3 ± 2.9 | -7.0 ± 1.9 |
| Month 18 (n=99,111) | -3.0 ± 2.5 | -1.9 ± 2.3 |
| Month 24 (n=86,109) | 3.2 ± 4.6 | 0.5 ± 3.7 |
Biopsy-confirmed acute rejection was defined according to updated Banff criteria (2007) for renal allograft rejection. Graft loss was defined as physical loss (nephrectomy or retransplantation), functional loss (requiring dialysis for greater than or equal to \[≥\]56 days with no return of graft function), or death.
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| Percentage of Participants With Biopsy-Confirmed Acute Rejection (BCAR), Graft Loss, or Death From Randomization to 24 Months Post-Transplantation | 11.5 | 2.4 |
Graft loss was defined as physical loss (nephrectomy or retransplantation), functional loss (requiring dialysis for ≥56 days with no return of graft function), or death.
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| Month 12 | 0.8 | 0.0 |
| Month 24 | 3.8 | 0.8 |
BCAR was defined according to updated Banff criteria (2007) for renal allograft rejection.
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| Month 6 | 1.5 | 0.0 |
| Month 12 | 5.3 | 0.8 |
| Month 18 | 6.9 | 1.6 |
| Month 24 | 8.4 | 1.6 |
Defined as the first BCAR occurring during the On-Therapy period based on the ITT population. Time to first BCAR was the days from transplantation to the date of BCAR.
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| Month 12 | 5.1 | 0.0 |
| Month 24 | 9.3 | 0.9 |
BCAR was categorized as antibody-mediated (AM) or T-cell. AM BCAR severity was graded as Grade I (mild), Grade II (moderate), and Grade III (severe). T-cell BCAR severity was graded as 'Grade Ia, Ib (mild), Grade IIa, IIb (moderate), and Grade III (severe). If a participant had both T-cell BCAR and antibody-mediated BCAR on the first rejection, the participant was counted in each category.
| participants | Sirolimus | Tacrolimus |
|---|---|---|
| Month 6, AM Grade I | 0 | 0 |
| Month 6, AM Grade II | 0 | 0 |
| Month 6, AM Grade III | 0 | 0 |
| Month 6, T-cell Grade Ia, Ib | 2 | 0 |
| Month 6, T-cell Grade IIa, IIb | 0 | 0 |
| Month 6, T-cell Grade III | 0 | 0 |
| Month 12, AM Grade I | 1 | 0 |
| Month 12, AM Grade II | 0 | 0 |
| Month 12, AM Grade III | 1 | 0 |
| Month 12, T-cell Grade Ia, Ib | 5 | 0 |
| Month 12, T-cell Grade IIa, IIb | 1 | 1 |
| Month 12, T-cell Grade III | 0 | 0 |
| Month 18, AM Grade I | 1 | 1 |
| Month 18, AM Grade II | 0 | 0 |
| Month 18, AM Grade III | 1 | 0 |
| Month 18, T-cell Grade Ia, Ib | 7 | 1 |
| Month 18, T-cell Grade IIa, IIb | 1 | 1 |
| Month 18, T-cell Grade III | 0 | 0 |
| Month 24, AM Grade I | 2 | 1 |
| Month 24, AM Grade II | 1 | 0 |
| Month 24, AM Grade III | 1 | 0 |
| Month 24, T-cell Grade Ia, Ib | 8 | 1 |
| Month 24, T-cell Grade IIa, IIb | 1 | 1 |
| Month 24, T-cell Grade III | 0 | 0 |
Number of participants who experienced an adverse event (AE) of rejection was used as the denominator in the determination of percentage of participants with antibody use in treatment of acute rejection.
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| On-therapy Period | 60.0 | 75.0 |
| Off-therapy Period | 40.0 | 25.0 |
Anemia was defined as hemoglobin less than or equal to (≤)10 grams per deciliter (g/dL); leukopenia was defined as white blood cell (WBC) count ≤2000 per cubic millimeters (/mm\^3); and thrombocytopenia was defined as platelets ≤100,000/mm\^3. Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article.
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| Baseline (n=131,122) | 4.6 | 1.6 |
| Month 12 (n=110,116) | 9.1 | 2.6 |
| Month 24 (n=89,112) | 3.4 | 4.5 |
Parameters assessed included total cholesterol (TC), triglycerides, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C); collected when participant was in a fasting state.
| mmol/L | Sirolimus | Tacrolimus |
|---|---|---|
| TC, Change at Month 12 (n=96,107) | 0.66 ± 0.10 | -0.12 ± 0.07 |
| TC, Change at Month 24 (n=74,88) | 0.51 ± 0.14 | -0.08 ± 0.09 |
| HDL-C, Change at Month 12 (n=90,99) | -0.00 ± 0.03 | 0.01 ± 0.02 |
| HDL-C, Change at Month 24 (n=69,81) | 0.01 ± 0.04 | 0.01 ± 0.03 |
| LDL-C, Change at Month 12 (n=87,98) | 0.43 ± 0.09 | -0.06 ± 0.07 |
| LDL-C, Change at Month 24 (n=66,78) | 0.34 ± 0.13 | -0.06 ± 0.08 |
| Triglycerides, Change at Month 12 (n=94,104) | 0.47 ± 0.11 | -0.18 ± 0.07 |
| Triglycerides, Change at Month 24 (n=73,86) | 0.43 ± 0.10 | 0.07 ± 0.12 |
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| Baseline, Anti-hypertensives | 95.4 | 92.7 |
| Month 12, Anti-hypertensives | 75.6 | 69.9 |
| Month 24, Anti-hypertensives | 61.8 | 65.9 |
| Baseline, Diabetes agents (insulin) | 46.6 | 47.2 |
| Month 12, Diabetes agents (insulin) | 26.0 | 26.0 |
| Month 24, Diabetes agents (insulin) | 18.3 | 25.2 |
| Baseline, Diabetes agents (non-insulin) | 14.5 | 17.9 |
| Month 12, Diabetes agents (non-insulin) | 10.7 | 13.8 |
| Month 24, Diabetes agents (non-insulin) | 9.2 | 13.0 |
| Baseline, Lipid-lowering agents | 46.6 | 60.2 |
| Month 12, Lipid-lowering agents | 55.7 | 54.5 |
| Month 24, Lipid-lowering agents | 47.3 | 49.6 |
| Baseline, ESAs | 50.4 | 43.1 |
| Month 12, ESAs | 7.6 | 2.4 |
| Month 24, ESAs | 3.8 | 2.4 |
Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article.
| UPr/Cr | Sirolimus | Tacrolimus |
|---|---|---|
| Baseline (n=127,120) | 0.180 ± 0.1413 | 0.195 ± 0.1477 |
| Month 12 (n=112,108) | 0.353 ± 0.3677 | 0.208 ± 0.2234 |
| Month 24 (n=102,106) | 0.510 ± 0.7887 | 0.300 ± 0.6154 |
Included ACEI or ARB use prior to randomization, during the on-therapy period (up to 19 to 21 months post randomization) and the off-therapy period (up to 24 months post-transplantation).
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| Pre-randomization | 46.6 | 46.3 |
| On-Therapy Period | 43.5 | 29.3 |
| Off-Therapy Period | 32.1 | 18.7 |
Includes adverse events based on categorization by the investigator as stomatitis, regardless of the event preferred term in Medical Dictionary for Regulatory Activities (MedDRA)
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| Percentage of Participants With Stomatitis | 28.2 | 1.6 |
Included treatments (analgesics, dental paste, topical antifungal, topical steroids, or other) prior to randomization, during the on-therapy period (up to 19 to 21 months post-randomization) and the off-therapy period (up to 24 months post-transplantation).
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| On-Therapy Period, any treatment | 17.6 | 2.4 |
| Off-Therapy Period, any treatment | 3.1 | 1.6 |
| On-Therapy, analgesics | 0.8 | 0.0 |
| On-Therapy, dental paste | 3.8 | 0.8 |
| On-Therapy, topical steroids | 5.3 | 0.0 |
| On-Therapy, other | 10.7 | 2.4 |
| Off-Therapy, topical steroids | 1.5 | 0.0 |
| Off-Therapy, other | 1.5 | 1.6 |
Ratio of hemoglobin A1c to normal hemoglobin.
| L/L | Sirolimus | Tacrolimus |
|---|---|---|
| Change From Pre-Randomization to 12 Months Post-Transplantation in Hemoglobin A1C (Liter Per Liter [L/L]) | -0.00 ± 0.00 | 0.00 ± 0.00 |
| mmol | Sirolimus | Tacrolimus |
|---|---|---|
| Change From Pre-Randomization to 12 Months Post-Transplantation in Fasting Glucose (mmol/L) | -0.50 ± 0.31 | -0.23 ± 0.20 |
| pmol/L | Sirolimus | Tacrolimus |
|---|---|---|
| Change From Pre-Randomization to 12 Months Post-Transplantation in Fasting Insulin (Picomoles Per Liter [Pmol/L]) | 27.25 ± 21.97 | 17.14 ± 11.85 |
| kg | Sirolimus | Tacrolimus |
|---|---|---|
| Change From Pre-Randomization to 12 Months Post-Transplantation in Weight (Kilograms [kg]) | 1.61 ± 0.51 | 2.03 ± 0.44 |
| cm | Sirolimus | Tacrolimus |
|---|---|---|
| Change From Pre-Randomization to 12 Months Post-Transplantation in Waist Circumference(Centimeters [cm]) | 1.13 ± 0.73 | 2.21 ± 1.00 |
The HOMA-IR measures insulin resistance based on fasting glucose and insulin measurements: HOMA-IR = fasting plasma glucose (mmol/L) multiplied by (\*) fasting plasma insulin in microunits per liter (µU/L) divided by (/) 22.5. Participants taking insulin within 12 hours were excluded from the analysis.
| insulin resistance score | Sirolimus | Tacrolimus |
|---|---|---|
| Change From Pre-Randomization to 12 Months Post-Transplantation in Homeostasis Model Assessment Insulin Resistance (HOMA-IR; Fasting) | 1.14 ± 1.37 | 1.10 ± 0.70 |
The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) as a percentage of a normal reference population. HOMA-B = 20 \* insulin (µU/L) / fasting plasma glucose (mmol/L) minus (-) 3.5 Participants taking insulin within 12 hours were excluded from the analysis.
| percentage beta cell function | Sirolimus | Tacrolimus |
|---|---|---|
| Change From Pre-Randomization to 12 Months Post-Transplantation in HOMA-Beta Cell (HOMA-B; Fasting) | 230.23 ± 214.68 | 26.05 ± 21.99 |
BMI = Weight (kg)/(Height\*Height) (square meters \[m\^2\]).
| kg/m^2 | Sirolimus | Tacrolimus |
|---|---|---|
| Change From Pre-Randomization to 12 Months Post-Transplantation in Body Mass Index (BMI; in Kilograms Per Square Meter [kg/m^2]) | 0.53 ± 0.18 | 0.75 ± 0.15 |
Participants were considered as having new onset diabetes during the On-therapy period if any of the below events emerged from baseline to Month 24: 1) at least 30 days continuous, or at least 25 days non-stop (without gap) use of any diabetic treatment after randomization; 2) a fasting glucose greater than or equal to (≥)126 milligrams per deciliter (mg/dL) after randomization; or 3) a non-fasting glucose ≥200 mg/dL after randomization, were included in the new-onset diabetes population. Events at Months 12 or 24 occurred from baseline to On-therapy Month 12 and from On-therapy Months 12 to 24, respectively.
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| New onset (n=82,72) | 18.3 | 5.6 |
| New onset at 1 year (n=82,72) | 14.6 | 2.8 |
| New onset at 2 years (n=70,70) | 4.3 | 2.9 |
Participants were considered as having new onset diabetes during the On-therapy period if any of the below events emerged between baseline and Month 12 or Month 24: 1) at least 30 days continuous, or at least 25 days non-stop (without gap) use of any diabetic treatment after randomization; 2) a fasting glucose ≥126 mg/dL after randomization; or 3) a non-fasting glucose ≥200 mg/dL after randomization.
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| Insulin (12-Month) | 13.3 | 0.0 |
| Insulin (24-Month) | 6.7 | 25.0 |
| Non-insulin (12-Month) | 13.3 | 0.0 |
| Non-Insulin (24-Month) | 13.3 | 0.0 |
Includes adverse events based on categorization by the investigator as 'infection', regardless of the event preferred term in MedDRA.
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| Percentage of Participants With Infection | 61.8 | 52.0 |
Includes adverse event terms reported by the investigator to be attributed to the organism 'cytomegalovirus', regardless of the preferred term in MedDRA.
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| Percentage of Participants With Cytomegalovirus (CMV) Infection | 3.1 | 3.3 |
Includes adverse event terms reported by the investigator to be attributed to the organism 'polyomavirus', regardless of the preferred term in MedDRA.
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| Percentage of Participants With Polyomavirus Infection | 3.8 | 7.3 |
Includes any adverse events based on categorization by the investigator as 'malignancy', regardless of the event preferred term in MedDRA.
| percentage of participants | Sirolimus | Tacrolimus |
|---|---|---|
| Percentage of Participants With Malignancy | 3.1 | 7.3 |
Collected over From randomization up to 24 months after transplantation (plus [+]4 weeks) for adverse events (AEs) and serious AEs (SAEs).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sirolimus | — | 50/131 (38.2%) | 116/131 (88.5%) |
| Tacrolimus | — | 38/123 (30.9%) | 88/123 (71.5%) |
| Event | Sirolimus | Tacrolimus |
|---|---|---|
| Transplant rejectionImmune system disorders | 11/131 | 1/123 |
| PneumoniaInfections and infestations | 6/131 | 3/123 |
| Urinary tract infectionInfections and infestations | 5/131 | 2/123 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/131 | 4/123 |
| PyrexiaGeneral disorders | 4/131 | 1/123 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/131 | 3/123 |
| Kidney transplant rejectionImmune system disorders | 3/131 | 1/123 |
| Renal artery stenosisRenal and urinary disorders | 3/131 | 0/123 |
| Hyperparathyroidism tertiaryEndocrine disorders | 0/131 | 2/123 |
| DiarrhoeaGastrointestinal disorders | 1/131 | 2/123 |
| Event | Sirolimus | Tacrolimus |
|---|---|---|
| Oedema peripheralGeneral disorders | 25/131 | 9/123 |
| DiarrhoeaGastrointestinal disorders | 22/131 | 12/123 |
| Upper respiratory tract infectionInfections and infestations | 22/131 | 13/123 |
| ProteinuriaRenal and urinary disorders | 19/131 | 2/123 |
| AcneSkin and subcutaneous tissue disorders | 19/131 | 1/123 |
| Mouth ulcerationGastrointestinal disorders | 16/131 | 0/123 |
| HeadacheNervous system disorders | 16/131 | 7/123 |
| DyslipidemiaMetabolism and nutrition disorders | 15/131 | 3/123 |
| Urinary tract infectionInfections and infestations | 14/131 | 8/123 |
| HyperlipidaemiaMetabolism and nutrition disorders | 14/131 | 4/123 |
Safety Population: all randomized participants who received at least one dose of the assigned therapy after randomization.
| Age, Continuous(years) | Sirolimus | Tacrolimus | Total |
|---|---|---|---|
| Mean | 50.7 ± 13.03 | 52.4 ± 12.05 | 51.5 ± 12.57 |
| Sex: Female, Male(Participants) | Sirolimus | Tacrolimus | Total |
|---|---|---|---|
| Female | 42 | 46 | 88 |
| Male | 89 | 77 | 166 |
The record gives a start of Jun 2009, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus